EP Patent

EP1721604A1 — Stable capsule preparation

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2006-11-15 · 20y expired

What this patent protects

A capsule in which an unstable active ingredient has been stabilized is obtained by lowering the moisture content of a solid preparation (granules, subtilis, tablets, etc.) containing a chemical unstable to moisture such as an imidazole PPI compound by drying or the like, and the…

USPTO Abstract

A capsule in which an unstable active ingredient has been stabilized is obtained by lowering the moisture content of a solid preparation (granules, subtilis, tablets, etc.) containing a chemical unstable to moisture such as an imidazole PPI compound by drying or the like, and then filling in a capsule comprising a water-soluble polysaccharide such as pullulan as the main component or a PEG-containing gelatin capsule. For the further stabilization, the capsule per se may be dried. The capsule preparation thus obtained is a stable capsule preparation with the use of a capsule being stable at a low moisture content which contains a chemical unstable to moisture such as an imidazole compound.

Drugs covered by this patent

Patent Metadata

Patent number
EP1721604A1
Jurisdiction
EP
Classification
—
Expires
2006-11-15
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.